Press Releases

Sangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II Communities With Stories Of Hope

RICHMOND, Calif., May 15, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced its support for International MPS Awareness Day and its commitment to the patients living with MPS I and MPS II and their families. In partnership with Living in the Light, an advocacy initiative to shine light on the lives of people with rare diseases through photography and compelling narratives, Sangamo highlights stories of hope from the MPS I and MPS II communities in the Patients & Families section of the Company's website.

Sangamo Therapeutics, Inc. (PRNewsFoto/Sangamo BioSciences, Inc.) (PRNewsFoto/)

"At Sangamo, our highest priority is to meet the needs of patients with commitment and compassion. We are proud to support MPS patients and their families, and honored to be partners in sharing their stories today in celebration of International MPS Awareness Day," said Dr. Sandy Macrae, CEO of Sangamo. "The Sangamo family is committed to translating our ground-breaking science into new genomic medicines that will transform the lives of these patients we are trying to serve. We invite our colleagues, friends and families around the world to recognize and help raise awareness for these rare genetic diseases."

Mucopolysaccharidosis Type I (MPS I) and MPS II are rare, genetic lysosomal storage disorders caused by a missing or insufficient enzyme that prevents cells from recycling waste, causing the buildup of complex sugars in the body called glycosaminoglycans, or GAGs. This leads to damage throughout the body, affecting vision and hearing, the joints, heart, and other tissues and organs. Sangamo is developing new genomic therapies for MPS I and MPS II using the Company's zinc finger nuclease (ZFN) genome editing technology. These genomic therapies are designed as a single treatment to provide life-long production of corrective IDUA and IDS enzymes for MPS I and MPS II respectively, from the patient's own liver and potentially eliminating the need for chronic enzyme replacement therapy, or ERT.

About Sangamo
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is advancing Phase 1/2 clinical programs in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has a strategic collaboration with Pfizer, Inc. for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences. For more information about Sangamo, visit the Company's website at

Forward Looking Statements
This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, statements relating to the potential of Sangamo's genomic therapies to treat MPS I and MPS II. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the dependence on the success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of Sangamo's therapeutics, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.


To view the original version on PR Newswire, visit:

SOURCE Sangamo Therapeutics, Inc.

Sign Up For E-Mail Alerts

Sign Up